Craft

Ultragenyx

Stock Price

$53.1

2024-10-28

Market Capitalization

$4.9 B

2024-10-28

Revenue

$560.2 M

FY, 2024

Ultragenyx Summary

Company Summary

Overview
Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases. It offers DOJOLVI, a treatment for children and adults with long-chain fatty acid oxidation disorders (LC-FAOD), and MEPSEVII, an enzyme replacement therapy (ERT) for mucopolysaccharidosis (MPS) VII.
Type
Public
Status
Active
Founded
2010
HQ
Novato, CA, US | view all locations
Website
https://www.ultragenyx.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Emil D. Kakkis

    Emil D. Kakkis, Founder, President and Chief Executive Officer, Director

  • Howard Horn

    Howard Horn, Chief Financial Officer and Executive Vice President, Corporate Strategy

  • Dennis Huang

    Dennis Huang, Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development

  • Eric Crombez

    Eric Crombez, Chief Medical Officer and Executive Vice President

Operating MetricsView all

Facilities Owned

1

FY, 2022

Facilities Leased

7

FY, 2022

Trials Products Approved

4

FY, 2022

LocationsView all

15 locations detected

  • Novato, CA HQ

    United States

    60 Leveroni Ct

  • Bedford, MA

    United States

    170 Middlesex Turnpike

  • Brisbane, CA

    United States

    5000 Marina Blvd

  • Miami, FL

    United States

    703 Waterford Way, suite 890

  • Somerville, MA

    United States

    100 Chestnut St

  • Woburn, MA

    United States

    19 Presidential Way 150 Presidential Way

and 9 others

Ultragenyx Financials

Summary Financials

Revenue (Q1, 2025)
$139.3M
Net income (Q1, 2025)
($151.1M)
Cash (Q1, 2025)
$127.1M
EBIT (Q1, 2025)
($142.9M)
Enterprise value
$4.8B

Footer menu